lncRNAs在甲状腺癌中的研究进展

Summary of the research progress of lncRNAs in thyroid cancer

甲状腺癌是最常见的内分泌恶性肿瘤,近年来发病率迅速上升。甲状腺癌的发生发展是大量遗传和表观遗传改变的过程。因此,明确甲状腺癌的发生发展机制是甲状腺癌治疗中必不可少的过程。长链非编码RNA(long noncoding RNA,lncRNA)最近被证实参与了癌症的进展。lncRNA主要通过调控基因表达,参与调控细胞分化、增殖、细胞周期、凋亡、迁移和侵袭等多种细胞生理过程。本文就多种lncRNAs的抑癌作用(如LINC00271、MEG3、NAMA等)和致癌作用(如ANRIL、FAL1、H19等)及其可能与甲状腺癌变的关系进行了广泛的讨论。总结了lncRNA靶向药物的策略和机制,描述了lncRNAs作为未来新的治疗靶点、诊断和预后标志物在甲状腺癌中的潜在作用。

Thyroid cancer is the most common endocrine malignant tumor.The development of thyroid cancer is a process of substantial genetic and epigenetic changes.Therefore,to clarify the pathogenesis of thyroid cancer is an essential process in the treatment of thyroid cancer.Long noncoding RNA(lncRNA)has recently been shown in cancer progression.lncRNA mainly regulates gene expression and participates in the regulation of cell differentiation,proliferation,cell cycle,apoptosis,migration,invasion and other cellular physiological processes.In this article,the anticancer effects of various lncRNAs(such as LINC00271,MEG3,NAMA,etc.),arcinogenic effects(such as ANRIL,FAL1,H19,etc.)and their possible relationship with thyroid carcinogenesis wasexten sively discussed.The approaches and mechanisms of lncRNA targeting drugs were summarized,and the potential role of lncRNAs as new therapeutic targets,diagnostic and prognostic markers in thyroid cancer was described.